HomeAI · summaries
Storia in 3 fonti
Dr Reddy’s aims to resume semaglutide supply by November after API fix
Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September. Financial results were impacted by a provision linked to the semaglutide active pharmaceutical ingredient. Despite disruptions, Dr Reddy's maintains its growth and profitability guidance for fiscal year 2027. The drugmaker anticipates supplying millions of semaglutide units this fiscal year.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Dr Reddy's Q1 profit falls 69% to ₹434 crore as lenalidomide transition weighs
Dr Reddy's Laboratories reported a 69% fall in Q1 profit to ₹434 crore as lenalidomide transition and semaglutide API impact offset base business growth.
- ·
thehindu.com
Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue
Dr. Reddy’s Q1 net profit drops 69% to ₹435.6 crore due to lower lenalidomide sales and semaglutide quality issues.
